Drugs / BPC 157
BPC 157
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02637284 | Oct 2015 → Feb 2016 | — | PharmaCotherapia d.o.o. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07437547 | Feb 2026 → Feb 2027 expected | acquired skeletal muscle disease | Hudson Biotech | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPC-157 | “This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing...” NCT07437547 ↗ |
| Known as | Bepecin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02637284 ↗ |
| Known as | PL-10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297358 ↗ |
| Known as | PL-14736 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297358 ↗ |
| Known as | PLD-116 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297358 ↗ |
| Modality | Peptide | “BPC 157 (BPC-157), an investigational peptide” NCT07437547 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297358 ↗ |
| Route | Subcutaneous | “eligible participants will be randomized 1:1 to receive subcutaneous BPC 157 or matching placebo once daily for 14 days.” NCT07437547 ↗ |